The Syneos Health Podcast: Early Signals
What are the signals today that will define the future of oncology treatment tomorrow?
The Syneos Health Podcast: Early Signals brings together leaders across biopharma, healthcare, academia and technology to explore the innovations reshaping drug development in oncology. Hosted by experts across Syneos Health, including Wael Harb, MD, Head of Research and Development and Scientific Strategy in oncology, each episode captures candid conversations about emerging science, evolving market dynamics and the trends poised to influence the future of patient care.
Tune in for timely perspectives on what's next—and what it means for the oncology industry, its stakeholders and most importantly its patients.
Subscribe to The Syneos Health Podcast: Early Signals for new episodes.
If there’s a topic you’d like us to explore, send us a message at podcasts@syneoshealth.com.
For more actionable, future-focused life sciences insights, visit the Syneos Health Insights Hub.
The Syneos Health Podcast: Early Signals
Latest Episodes
Early Signals at ASCO 2026 | Can Real-World Evidence Bring Research Closer to Patients?
Can real-world evidence do more than support regulatory decisions? Could it fundamentally change how clinical research is designed, delivered and connected to patient care?In this episode of The Syneos Health Podcast: Early Signals,
Early Signals at ASCO 2026 | Beyond Digitization: How AI Is Transforming Clinical Trial Operations
If clinical trials are already digitized, why do clinical operations remain so complex, manual and resource-intensive?In this episode of Early Signals, Wael Harb, MD, speaks with
Early Signals at ASCO 2026 | Can TIL Therapy Reach More Patients?
Can the next generation of tumor-infiltrating lymphocyte (TIL) therapies overcome the barriers that have limited broader adoption of cell therapy in solid tumors? In this episode of Early Signals, recorded live at ASC...
Early Signals at ASCO 2026 | Is MRD Ready to Guide Drug Development?
Can minimal residual disease (MRD) do more than measure response? Could it redefine how multiple myeloma therapies are developed, approved and ultimately used to guide patient care? In this episode of Early Si...
Early Signals at ASCO 2026 | Can AI Predict Cancer's Next Move? Rethinking Drug Resistance in Oncology
Can AI predict cancer's next move before drug resistance develops?Drug resistance remains one of the greatest challenges in oncology drug development. Most targeted therapies are designed to treat today's tumor biology, leaving ...